GYRE

Over the past six months, Gyre Therapeutics experienced several stock events. On May 4, 2026, the acquisition of Cullgen Inc. for approximately $300 million in an all-stock transaction, expanding into targeted protein degradation, resulted in a +1.54% stock change. On May 7, 2026, the Q1 2026 financial results, which reported ETUARY™ sales of $21.0 million (a slight decrease from Q1 2025 due to seasonal fluctuation), led to a -12.06% stock change. The NMPA's acceptance of F351's New Drug Application for CHB-induced liver fibrosis on May 12, 2026, saw a -0.27% change. Q2 2026 financial results on August 7, 2026, reported revenues of $29.1 million (a 2% decrease from Q2 2025), with increased ETUARY™ sales offset by lower Contiva™ and Etorel™ revenues due to China's national centralized procurement program, resulting in a +4.22% stock change. In September 2026, participation in investor conferences highlighted the company's profitable China commercial business and pipeline, contributing to positive stock movement. In October 2026, analyst rating changes saw Zacks Research and Wall Street Zen upgrade the stock to a 'hold' rating, with a consensus 'Hold' rating and an average price target of $16.00. Overall, the stock has seen a -3.2% change over the past 12 months and a -0.8% return over the past 6 months.